The effects of 3-hydroxypyridine (3-HP) derivatives on platelet aggregation and platelet phosphodiesterase (PDE) of cyclic nucleotides (cAMP-dependent) were studied. It was shown that some derivatives of 3-HP inhibit platelet aggregation (the most pronounced effect was exerted by 2-benzyl-3- oxypyridine ). Several derivatives o 3-HP given in a concentration 10(-3) M were discovered to inhibit PDE by 40 to 75%. No correlation was found between the efficacy of 3-HP as antiaggregation agents and PDE inhibitors.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Electrochemical study of anti-platelets tirofiban HCl in dosage form using nanomaterials modified sensors: developed and green assessed by eco-scale and complex-GAPI approach.
BMC Chem
January 2025
National Organization for Drug Control and Research (NODCAR), P.O.Box 29, Cairo, Egypt.
Tirofiban hydrochloride is used to inhibit platelet aggregation, which has a significant impact on the treatment of congestive heart failure the most common cause of death according to WHO. Therefore, its quantification in pharmaceutical dosage form is critical. In this work, an electrochemical method for the determination of tirofiban HCl in pharmaceutical dosage form was developed and validated.
View Article and Find Full Text PDFDecoding platelet loss in the hypoxic brain: What could go wrong?
J Physiol
January 2025
Cerebrovascular Health Exercise and Environmental Research Sciences Laboratory (CHEERS), Department of Exercise Science, Physical & Health Education, University of Victoria, Victoria, BC, Canada.
L. protects cerebral ischemia/reperfusion injury via arachidonic acid/p53-mediated apoptosis axis.
Front Pharmacol
December 2024
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Introduction: Stroke is a debilitating disease and the second leading cause of death worldwide, of which ischemic stroke is the dominant type. L., also known as safflower, has been used to treat cerebrovascular diseases, especially ischemic stroke in many Asian countries.
View Article and Find Full Text PDFIntracranial hemorrhagic events associated with flow diversion treatment: a retrospective analysis from a single academic institution.
Neurosurg Rev
January 2025
Neurosurgical Service, Harvard Medical School, Beth Israel Deaconess Medical Center, 110 Francis Street, Boston, MA, 02215, USA.
Intracranial hemorrhages are highly concerning but underreported complications related to flow diversion (FD) treatment of intracranial aneurysms. Herein, we aimed to characterize these complications and the factors influencing their occurrence. We retrospectively reviewed patients treated with FD from 2013 to 2023 at a single U.
View Article and Find Full Text PDFEfficacy and safety of tirofiban in acute ischemic stroke patients with ideal reperfusion: A cohort study of LAA and CE subgroups.
Eur J Neurol
January 2025
Department of Neurology, Xinqiao Hospital and the Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Background And Objectives: Despite achieving ideal reperfusion (eTICI = 3) through endovascular treatment (EVT), some acute ischemic stroke (AIS) patients still experience poor outcomes. This study aims to evaluate the efficacy and safety of tirofiban in AIS patients with ideal reperfusion, focusing on its effects in large artery atherosclerosis (LAA) and cardioembolic (CE) stroke.
Methods: A total of 474 AIS patients from the RESCUE-BT database were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!